TBPH (TBPH)

$877M
Market Cap
7.6
P/E Ratio
Beta
Dividend Yield
Piotroski 6/9

Quantitative Summary

Deterministic

Financial health is average: Piotroski 6/9.

Generated deterministically from quant metrics and financial statements. Not a recommendation.

Algorithmic Teardown

AI-Generated

The capital allocation efficiency of this entity is exceptional, evidenced by a robust 23.3% return on invested capital that suggests strong operational leverage and pricing power relative to the cost of equity. This high ROIC is underpinned by an extraordinary net margin expansion to 98.5%, indicating either dominant market positioning or significant non-operating income components rather than traditional gross profit dynamics, while a Piotroski F-Score of 6/9 signals solid fundamental strength with minor deteriorations in financial health over the trailing period. Despite these robust profitability metrics and impressive revenue growth accelerating at 66.9% year-over-year, the DuPont decomposition implies that earnings generation is driven almost exclusively by margin expansion rather than asset turnover or leverage increases, creating a unique valuation profile distinct from standard industrial peers.

Valuation multiples currently compress significantly relative to the company's historical trajectory and sector norms, with a P/E ratio of 7.6x suggesting the market may be discounting future cash flow potential due to uncertainty regarding sustainability or one-time nature of current earnings. A discounted cash flow analysis anchors fair value at $78, implying that if growth assumptions hold steady, the current price offers substantial upside relative to intrinsic worth; however, this wide gap between implied DCF values and realized multiples indicates the market is pricing in severe downside risks or a terminal decline in growth rates not yet reflected in recent quarterly results. The dissonance between high-quality fundamentals and depressed valuation metrics creates an asymmetric setup where the stock trades at a discount despite generating returns well above typical cost of capital benchmarks.

Risk assessment must weigh the high revenue velocity against the sustainability of near-perfect margins, as such figures often precede mean reversion or regulatory scrutiny absent in standard Fama-French factor models for mature sectors. While insider activity data is unavailable to confirm alignment between management and shareholder interests, the combination of a low multiple and strong ROIC suggests potential value capture if macroeconomic headwinds ease or if the revenue growth proves durable beyond current projections. Investors must scrutinize whether the 98.5% margin is structural or transient before concluding that the current pricing accurately reflects long-term risk-adjusted returns.

Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.

DCF Sandbox

Interactive

Sensitivity Matrix

TG ↓ / WACC →8%10%12%
2%$94$71$57
3%$108$78$61
4%$130$88$67

Center = base case. Green = >10% upside, Red = >10% downside vs .

Pre-computed DCF: WACC=10.0%, terminal growth 3%. Fair value $78 (+0.0%). Not investment advice.

Price Chart with Moving Averages

Loading chart...
SMA 50 SMA 200

Quant Health Deep Dive

6/9
Piotroski F-Score
Average — mixed operational signals

Profitability & Value Creation

98.5%
Net Margin
23.3%
ROIC
+66.9%
Revenue Growth (YoY)
+287.7%
Earnings Growth (YoY)
238.5M
Free Cash Flow

Balance Sheet Health

0.64x
Debt / Equity
10.93x
Current Ratio
53.5x
Interest Coverage
134.5M
EBITDA

Earnings Surprise History

Q4
✗ Miss
Est: $-0.09
Act: $-0.17
-92.7%
Q3
✓ Beat
Est: $-0.12
Act: $-0.08
+32.6%
Q2
✓ Beat
Est: $-0.05
Act: $0.04
+187.0%
Q1
✗ Miss
Est: $0.33
Act: $0.06
-81.9%

EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.

Underwater (Drawdown from Peak)

How far below the all-time high the price has been over time. Deeper = more pain for holders.

Loading drawdown chart...

Rolling 60-Day Beta vs S&P 500 (VOO)

How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.

Loading beta chart...
Rolling Beta Market (β = 1.0)

Fundamentals

12.6
Forward P/E
PEG Ratio
2.93
Price/Book
614919
Avg Volume
$21.03
52W High
$8.33
52W Low
52W Range Position

ETF Contagion Visualizer

Simulate a price drop in TBPH to visualize passive redemption contagion across ETFs and collateral stocks.

TBPH Shock
-0%
Est. Passive Redemption
$0
Systemic Risk
STABLE
TBPHEpicenterVHTETFVFMOETFXPHETFLLYLow RiskJNJLow RiskABBVMed RiskUNHMed RiskMRKLow Risk
TBPH Price Drop (%)0

If TBPH (TBPH) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies Eli Lilly & Co. (LLY) as the most exposed collateral stock, sharing 2 ETFs with TBPH. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.

Contagion model based on shared ETF exposure and constituent weights across 3 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.

TBPH Ownership Dynamics

Ticker
TBPH

ETFs with Highest TBPH Exposure

Float lock-up computed from 3 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).

TBPH Capital Efficiency

How efficiently does TBPH convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.

Free Cash Flow
$238M
EBITDA
$135M
FCF Conversion
177%
Reinvestment Rate
-77%
177% of EBITDA → Free Cash
0% (cash burn)25% (low)50% (efficient)100% (pure cash)

TBPH converts 177% of its EBITDA into free cash flow, an exceptional conversion rate indicating an asset-light business model with minimal capital reinvestment drag.

Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.

Fails-to-Deliver (FTD) History

SEC-reported settlement failures. Elevated FTDs can indicate high short-selling pressure, operational settlement issues, or naked shorting activity.

DateFailed SharesClose PriceNotional Value
2026-05-1321,413$16.48$352,886.24
2026-04-16116$16.64$1,930.24
2026-04-0958$16.60$962.8
2026-03-2639,518$15.29$604,230.22
2026-03-2522,321$14.90$332,582.9
2026-03-2311$14.33$157.63
2026-03-051,105$13.67$15,105.35
2026-03-0443$13.96$600.28
2026-02-04980$19.99$19,590.2
2026-02-0222$18.94$416.68
2026-01-2653$20.24$1,072.72
2026-01-22439$20.37$8,942.43
2026-01-21741$20.42$15,131.22
2026-01-145$20.33$101.65
2026-01-09262$19.02$4,983.24
2026-01-05571$18.15$10,363.65
2025-12-29230$18.84$4,333.2
2025-12-15545$18.17$9,902.65
2025-12-1027$17.81$480.87
2025-11-21787$17.90$14,087.3

Source: SEC Regulation SHO FTD data. Data is reported with a ~30 day delay. High FTD quantities relative to average daily volume may indicate settlement stress.

Compare TBPH to Peers

Quant metrics computed deterministically from financial statements and price data. Updated: N/A.

SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.